Vygenerované: 14.12.2025 18:32:28
Súhrn: - Home - Medical news & Guidelines - Anesthesiology - Cardiology and CTVS - Critical Care - Dentistry - Dermatology - Diabetes and Endocrinology - ENT - Gastroenterology - Medicine - Nephrology - Neurology - Obstretics-Gynaecology - Oncology - Ophthalmology - Orthopaedics - Pediatrics-Neonatology - Psychiatry - Pulmonology - Radiology - Surgery - Urology - Laboratory Medicine - Diet - Nursing - Paramedical - Physiotherapy - Health news - Fact Check - Bone Health Fact Check - Brain Health Fact Check - Cancer Related Fact Check - Child Care Fact Check - Dental and oral health fact check - Diabetes and metabolic health fact check - Diet and Nutrition Fact Check - Eye and ENT Care Fact Check - Fitness fact check - Gut health fact check - Heart health fact check - Kidney health fact check - Medical education fact check - Men's health fact check - Respiratory fact check - Skin and hair care fact check - Vaccine and Immunization fact check - Women's health fact check - AYUSH - State News - Andaman and Nicobar Islands - Andhra Pradesh - Arunachal Pradesh - Assam - Bihar - Chandigarh - Chattisgarh - Dadra and Nagar Haveli - Daman and Diu - Delhi - Goa - Gujarat - Haryana - Himachal Pradesh - Jammu & Kashmir - Jharkhand - Karnataka - Kerala - Ladakh - Lakshadweep - Madhya Pradesh - Maharashtra - Manipur - Meghalaya - Mizoram - Nagaland - Odisha - Puducherry - Punjab - Rajasthan - Sikkim - Tamil Nadu - Telangana - Tripura - Uttar Pradesh - Uttrakhand - West Bengal - Medical Education - Industry Nerve block may reduce opioid use in infants undergoing cleft palate surgery: Study For infants undergoing cleft palate surgery, local anesthetic injection targeting the maxillary nerve of the face may reduce or eliminate the need for opioid medications to control postoperative pain, reports a study in The Journal of Craniofacial Surgery "Our study presents preliminary but promising results suggesting that suprazygomatic maxillary nerve block [SMNB] may reduce perioperative opioid consumption in pediatric primary clefts particularly cleft palate closure," comments senior author Rutger M The journal is published in the Lippincott portfolio by Wolters Kluwer.
Doplnenie: Schols, MD, PhD, of MosaKids Children’s Hospital, Maastricht, the Netherlands.
Súhrn: - Home - Medical news & Guidelines - Anesthesiology - Cardiology and CTVS - Critical Care - Dentistry - Dermatology - Diabetes and Endocrinology - ENT - Gastroenterology - Medicine - Nephrology - Neurology - Obstretics-Gynaecology - Oncology - Ophthalmology - Orthopaedics - Pediatrics-Neonatology - Psychiatry - Pulmonology - Radiology - Surgery - Urology - Laboratory Medicine - Diet - Nursing - Paramedical - Physiotherapy - Health news - Fact Check - Bone Health Fact Check - Brain Health Fact Check - Cancer Related Fact Check - Child Care Fact Check - Dental and oral health fact check - Diabetes and metabolic health fact check - Diet and Nutrition Fact Check - Eye and ENT Care Fact Check - Fitness fact check - Gut health fact check - Heart health fact check - Kidney health fact check - Medical education fact check - Men's health fact check - Respiratory fact check - Skin and hair care fact check - Vaccine and Immunization fact check - Women's health fact check - AYUSH - State News - Andaman and Nicobar Islands - Andhra Pradesh - Arunachal Pradesh - Assam - Bihar - Chandigarh - Chattisgarh - Dadra and Nagar Haveli - Daman and Diu - Delhi - Goa - Gujarat - Haryana - Himachal Pradesh - Jammu & Kashmir - Jharkhand - Karnataka - Kerala - Ladakh - Lakshadweep - Madhya Pradesh - Maharashtra - Manipur - Meghalaya - Mizoram - Nagaland - Odisha - Puducherry - Punjab - Rajasthan - Sikkim - Tamil Nadu - Telangana - Tripura - Uttar Pradesh - Uttrakhand - West Bengal - Medical Education - Industry Hemgenix Gene Therapy Shows Sustained Benefits Over 5 Years in Hemophilia B: NEJM USA: Final HOPE-B trial results published in The New England Journal of Medicine have revealed that patients with hemophilia B maintained low bleeding rates and stable endogenous factor IX levels for five years following a single infusion of etranacogene dezaparvovec (Hemgenix) 52 between months 7 and 60 post-treatment, representing a 63% reduction - Annual factor IX use for prophylaxis and bleeding treatment dropped by 96%, from 257,339 IU per year before therapy to 10,924 IU per year post-treatment.
Doplnenie: 52 between months 7 and 60 post-treatment, representing a 63% reduction.
Súhrn: ) to enable its use for the treatment of type 2 diabetes that is not satisfactorily controlled in children and adolescents aged 10 year and older It can be used as monotherapy in patients who cannot take metformin or as an add-on to other diabetes medicines It is also currently indicated for individuals who are obese (BMI of ≥ 30) or overweight (BMI between 27 and 30) and have at least one weight-related health problem.
Doplnenie: It can be used as monotherapy in patients who cannot take metformin or as an add-on to other diabetes medicines.
Súhrn: - Home - Medical news & Guidelines - Anesthesiology - Cardiology and CTVS - Critical Care - Dentistry - Dermatology - Diabetes and Endocrinology - ENT - Gastroenterology - Medicine - Nephrology - Neurology - Obstretics-Gynaecology - Oncology - Ophthalmology - Orthopaedics - Pediatrics-Neonatology - Psychiatry - Pulmonology - Radiology - Surgery - Urology - Laboratory Medicine - Diet - Nursing - Paramedical - Physiotherapy - Health news - Fact Check - Bone Health Fact Check - Brain Health Fact Check - Cancer Related Fact Check - Child Care Fact Check - Dental and oral health fact check - Diabetes and metabolic health fact check - Diet and Nutrition Fact Check - Eye and ENT Care Fact Check - Fitness fact check - Gut health fact check - Heart health fact check - Kidney health fact check - Medical education fact check - Men's health fact check - Respiratory fact check - Skin and hair care fact check - Vaccine and Immunization fact check - Women's health fact check - AYUSH - State News - Andaman and Nicobar Islands - Andhra Pradesh - Arunachal Pradesh - Assam - Bihar - Chandigarh - Chattisgarh - Dadra and Nagar Haveli - Daman and Diu - Delhi - Goa - Gujarat - Haryana - Himachal Pradesh - Jammu & Kashmir - Jharkhand - Karnataka - Kerala - Ladakh - Lakshadweep - Madhya Pradesh - Maharashtra - Manipur - Meghalaya - Mizoram - Nagaland - Odisha - Puducherry - Punjab - Rajasthan - Sikkim - Tamil Nadu - Telangana - Tripura - Uttar Pradesh - Uttrakhand - West Bengal - Medical Education - Industry Capillary Refill-Targeted Resuscitation Improves Outcomes in Early Septic Shock: JAMA A new study published in the Journal of American Medical Association showed that for the key composite outcome in early septic shock, a customized hemodynamic resuscitation approach that focused on capillary refill time performed better than standard treatment, primarily by shortening the time needed for critical support This approach seeks to lessen fluid overload, increase tissue oxygenation, and perhaps improve results during the crucial early hours of treatment by concentrating on microcirculatory perfusion rather than just global metrics Thus, this study looked in to the impact of a customized hemodynamic resuscitation procedure that targets capillary refill time (CRT-PHR) on a hierarchical composite outcome comprising length of hospital stay, duration of vital support, and fatality.
Doplnenie: Thus, this study looked in to the impact of a customized hemodynamic resuscitation procedure that targets capillary refill time (CRT-PHR) on a hierarchical composite outcome comprising length of hospital stay, duration of vital support, and fatality.